The global cryptococcosis market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to accelerate the growth of the market during the forecast period include the growing prevalence of cryptococcosis and the availability of advanced treatment. Cryptococcosis is a fungal infection which is caused by cryptococcus neoformans and Cryptococcus gattii which primarily affect the central nervous system and the lungs. People with diseases such as AIDS, Hodgkin lymphoma, other lymphomas, sarcoidosis, and solid organ transplantation with weakened immune systems are generally more susceptible to this type of infection. Cryptococcosis is usually acquired by inhalation of dust-containing yeast cells which typically affects the lungs. 

Cryptococcosis symptoms include fever, malaise, cough, hemoptysis (bloody or blood-tinged sputum), headache, vision changes (blurry or double vision, photophobia), and so on. Cryptococcosis diagnosis is clinical and microscopic, which is confirmed by culture or fixed-tissue staining. According to the United Nations Program on HIV/AIDS and the World Health Organization (WHO), globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 mortalities approximately. According to the Centers for Disease Control and Prevention and WHO, it is estimated that globally every year 220,000 cases of cryptococcal meningitis occur among people with HIV/AIDS, resulting in nearly 181,000 mortalities. However, adverse effects associated with the use of medication is likely to restrain the market growth. 

Cryptococcosis infects humans and animals, usually by inhalation of the fungus, which results in lung infection that may spread to the brain, causing meningoencephalitis. Flucytosine is a small, water-soluble molecule that is a nucleoside analog antifungal drug that acts by disrupting pyrimidine metabolism in the fungal cell nucleus. Flucytosine is generally given as first-line treatment in combination with other antifungal medications. Flucytosine was major revenue holding segment because it is given as a first-line treatment in combination with other antifungal medications. According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 mortalities approximately. The increasing prevalence of cryptococcosis and increasing new and advanced treatment opportunities are the key factors that are boosting the growth of the market during the forecast period.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027

Segment Covered- 

o By Treatment

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Pfizer Inc., Astellas Pharma Inc., and Bristol-Myers Squibb Co., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?

How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cryptococcosis Market Report by Segment

By Treatment

• Amphotericin B
• Flucytosine
• Fluconazole
• Others

Global Cryptococcosis Market by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa